
## James Robert Brasic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4286215/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand <sup>18</sup> F-AV-45 (Flobetapir F 18). Journal of Nuclear Medicine, 2010, 51, 913-920.	5.0	607
2	Sex Differences in Striatal Dopamine Release in Healthy Adults. Biological Psychiatry, 2006, 59, 966-974.	1.3	315
3	Relationships Among Ventral Striatal Dopamine Release, Cortisol Secretion, and Subjective Responses to Amphetamine. Neuropsychopharmacology, 2005, 30, 821-832.	5.4	295
4	Increased Occupancy of Dopamine Receptors in Human Striatum during Cue-Elicited Cocaine Craving. Neuropsychopharmacology, 2006, 31, 2716-2727.	5.4	280
5	Elevated Intrasynaptic Dopamine Release in Tourette's Syndrome Measured by PET. American Journal of Psychiatry, 2002, 159, 1329-1336.	7.2	236
6	Mechanisms of Dopaminergic and Serotonergic Neurotransmission in Tourette Syndrome: Clues from an In Vivo Neurochemistry Study with PET. Neuropsychopharmacology, 2008, 33, 1239-1251.	5.4	227
7	Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology, 2019, 44, 598-605.	5.4	207
8	Alterations of Central Dopamine Receptors Before and After Gastric Bypass Surgery. Obesity Surgery, 2010, 20, 369-374.	2.1	189
9	Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. NeuroImage, 2010, 52, 1505-1513.	4.2	186
10	Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse, 2008, 62, 91-100.	1.2	180
11	The Dopamine Transporter is Decreased in the Striatum of Subjects with Restless Legs Syndrome. Sleep, 2011, 34, 341-347.	1.1	126
12	Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. NeuroImage, 2003, 18, 975-989.	4.2	117
13	VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. Journal of Neurochemistry, 2008, 105, 78-90.	3.9	111
14	The Role of Dopamine in Value-Based Attentional Orienting. Current Biology, 2016, 26, 550-555.	3.9	96
15	<sup>18</sup> F-FPEB, a PET Radiopharmaceutical for Quantifying Metabotropic Glutamate 5 Receptors: A First-in-Human Study of Radiochemical Safety, Biokinetics, and Radiation Dosimetry. Journal of Nuclear Medicine, 2013, 54, 388-396.	5.0	95
16	Impulsivity and chronic stress are associated with amphetamine-induced striatal dopamine release. NeuroImage, 2007, 36, 153-166.	4.2	93
17	Increased Synaptic Dopamine in the Putamen in Restless Legs Syndrome. Sleep, 2013, 36, 51-57.	1.1	93
18	History of childhood adversity is positively associated with ventral striatal dopamine responses to amphetamine. Psychopharmacology, 2014, 231, 2417-2433.	3.1	89

#	Article	IF	CITATIONS
19	Characterization of 3 Novel Tau Radiopharmaceuticals, <sup>11</sup> C-RO-963, <sup>11</sup> C-RO-643, and <sup>18</sup> F-RO-948, in Healthy Controls and in Alzheimer Subjects. Journal of Nuclear Medicine, 2018, 59, 1869-1876.	5.0	81
20	Human Brain Imaging of α7 nAChR with [18F]ASEM: a New PET Radiotracer for Neuropsychiatry and Determination of Drug Occupancy. Molecular Imaging and Biology, 2014, 16, 730-738.	2.6	69
21	A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies. NeuroImage, 2009, 44, 661-670.	4.2	51
22	Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboonPapio anubis. Synapse, 2005, 56, 94-99.	1.2	47
23	Multi-graphical analysis of dynamic PET. NeuroImage, 2010, 49, 2947-2957.	4.2	47
24	Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers. Neuropsychopharmacology, 2013, 38, 504-512.	5.4	47
25	Brain PET Imaging of α7-nAChR with [18F]ASEM: Reproducibility, Occupancy, Receptor Density, and Changes in Schizophrenia. International Journal of Neuropsychopharmacology, 2018, 21, 656-667.	2.1	47
26	PET Imaging of High-Affinity α4β2 Nicotinic Acetylcholine Receptors in Humans with <sup>18</sup> F-AZAN, a Radioligand with Optimal Brain Kinetics. Journal of Nuclear Medicine, 2013, 54, 1308-1314.	5.0	46
27	Linking dopaminergic reward signals to the development of attentional bias: A positron emission tomographic study. Neurolmage, 2017, 157, 27-33.	4.2	46
28	Hallucinations. Perceptual and Motor Skills, 1998, 86, 851-877.	1.3	43
29	An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. Neurolmage, 2006, 33, 550-563.	4.2	42
30	GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding. Journal of the Neurological Sciences, 2015, 356, 118-123.	0.6	42
31	Striatal Dopamine Release and Family History of Alcoholism. Alcoholism: Clinical and Experimental Research, 2006, 30, 1143-1151.	2.4	41
32	Bone mineral density in postmenopausal Chinese women treated with calcium fortification in soymilk and cow's milk. Osteoporosis International, 2012, 23, 1563-1570.	3.1	41
33	Objectively measured sleep and β-amyloid burden in older adults: A pilot study. SAGE Open Medicine, 2014, 2, 205031211454652.	1.8	41
34	An In Vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients. Molecular Imaging and Biology, 2013, 15, 230-237.	2.6	36
35	Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers. PLoS ONE, 2014, 9, e113694.	2.5	36
36	Metabotropic glutamate receptor 5 tracer [18F]-FPEB displays increased binding potential in postcentral gyrus and cerebellum of male individuals with autism: a pilot PET study. Cerebellum and Ataxias, 2018, 5, 3.	1.9	36

JAMES ROBERT BRASIC

#	Article	IF	CITATIONS
37	ADVERSE EFFECTS OF CLOMIPRAMINE. Journal of the American Academy of Child and Adolescent Psychiatry, 1997, 36, 1165-1166.	0.5	35
38	Brain imaging research: Does the science serve clinical practice?. International Review of Psychiatry, 2007, 19, 541-558.	2.8	33
39	Risky decision-making and ventral striatal dopamine responses to amphetamine: A positron emission tomography [11C]raclopride study in healthy adults. NeuroImage, 2015, 113, 26-36.	4.2	29
40	Positron emission tomography experience with 2â€{ <sup>18</sup> F]fluoroâ€3â€{2( <i>s</i> )â€azetidinylmethoxy)pyridine (2â€{ <sup>18</sup> F]fa) in the livi human brain of smokers with paranoid schizophrenia. Synapse, 2012, 66, 352-368.	ing.2	28
41	ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology, 2015, 232, 2863-2872.	3.1	28
42	Molecular imaging of autism spectrum disorder. International Review of Psychiatry, 2017, 29, 530-554.	2.8	28
43	Quinine-Induced Thrombocytopenia in a 64-Year-Old Man Who Consumed Tonic Water to Relieve Nocturnal Leg Cramps. Mayo Clinic Proceedings, 2001, 76, 863-864.	3.0	27
44	Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology, 2013, 229, 245-252.	3.1	26
45	Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. NeuroImage, 2013, 75, 282-290.	4.2	26
46	Single photon emission computed tomography experience with ( <i>S</i> )â€5â€[ <sup>123</sup> 1]iodoâ€3â€{2â€a2etidinylmethoxy)pyridine in the living human brain of smok and nonsmokers. Synapse, 2009, 63, 339-358.	ers1.2	24
47	An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy, 2020, 21, 139-145.	1.8	23
48	Clinical Assessment of Self-Injurious Behavior. Psychological Reports, 1997, 80, 155-160.	1.7	20
49	Hyperkinesias in a Prepubertal Boy with Autistic Disorder Treated with Haloperidol and Valproic Acid. Psychological Reports, 1997, 80, 163-170.	1.7	20
50	Neurodevelopmental hypothesis of schizophrenia: a central sensory disturbance. Medical Hypotheses, 2000, 55, 314-318.	1.5	20
51	A low-cost quantitative continuous measurement of movements in the extremities of people with Parkinson's disease. MethodsX, 2019, 6, 169-189.	1.6	20
52	Correlation of the vesicular acetylcholine transporter densities in the striata to the clinical abilities of women with rett syndrome. Synapse, 2012, 66, 471-482.	1.2	19
53	Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Idiopathic Autism Spectrum Disorder and Fragile X Syndrome: A Pilot Study. International Journal of Molecular Sciences, 2021, 22, 2863.	4.1	19
54	CLINICIAN SAFETY. Psychiatric Clinics of North America, 1999, 22, 923-940.	1.3	18

#	Article	IF	CITATIONS
55	Should People with Nocturnal Leg Cramps Drink Tonic Water and Bitter Lemon?. Psychological Reports, 1999, 84, 355-367.	1.7	18
56	Movements in autistic disorder. Medical Hypotheses, 1999, 53, 48-49.	1.5	18
57	Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence after a short-term abstinence. Psychiatry Research - Neuroimaging, 2014, 221, 92-96.	1.8	18
58	Progressive Catatonia. Psychological Reports, 1999, 84, 239-246.	1.7	17
59	Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone pain palliation treatment. Nuclear Medicine Communications, 2012, 33, 90-96.	1.1	17
60	The role of lumateperone in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532110340.	2.7	17
61	Behavioral Effects of Clomipramine on Prepubertal Boys With Autistic Disorder and Severe Mental Retardation. CNS Spectrums, 1998, 3, 39-46.	1.2	16
62	Are dopamine receptor and transporter changes in Rett syndrome reflected in Mecp2-deficient mice?. Experimental Neurology, 2018, 307, 74-81.	4.1	15
63	Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome. Brain Sciences, 2020, 10, 899.	2.3	15
64	Beta-amyloid (Aβ) uptake by PET imaging in older HIV+ and HIV- individuals. Journal of NeuroVirology, 2020, 26, 382-390.	2.1	15
65	Dyskinesias Subside off All Medication in a Boy with Autistic Disorder and Severe Mental Retardation. Psychological Reports, 1997, 81, 755-767.	1.7	14
66	In vivo imaging of neurotransmitter systems in neuropsychiatry. Clinical Neuroscience Research, 2001, 1, 35-45.	0.8	14
67	Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use. CNS Drugs, 2015, 29, 313-330.	5.9	14
68	Positron emission tomography–a tool for identifying the effects of alcohol dependence on the brain. Alcohol Research, 2003, 27, 161-73.	1.0	14
69	Quantitative Multi-modal Brain Autoradiography of Glutamatergic, Dopaminergic, Cannabinoid, and Nicotinic Receptors in Mutant Disrupted-In-Schizophrenia-1 (DISC1) Mice. Molecular Imaging and Biology, 2015, 17, 355-363.	2.6	13
70	Psychoactive Medication Quality Assurance Rating Survey (PQRS). Journal of Developmental and Physical Disabilities, 1997, 9, 311-336.	1.6	12
71	Neuromotor Assessment and Autistic Disorder. Autism, 2000, 4, 287-298.	4.1	12
72	Dose effects of triazolam on brain activity during episodic memory encoding: a PET study. Psychopharmacology, 2006, 188, 445-461.	3.1	12

#	Article	IF	CITATIONS
73	P4â€185: First inâ€human PET study of 3 novel tau radiopharmaceuticals: [ <sup>11</sup> C]RO6924963, [ <sup>11</sup> C]RO6931643, and [ <sup>18</sup> F]RO6958948. Alzheimer's and Dementia, 2015, 11, P850.	0.8	12
74	Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 235-241.	2.2	12
75	PETS AND HEALTH. Psychological Reports, 1998, 83, 1011.	1.7	12
76	Diagnosis of Benign Solitary Fibrous Tumors by Positron Emission Tomography. Southern Medical Journal, 2004, 97, 1264-1267.	0.7	11
77	The Effect of Vitamin D Supplementation on the Severity of Symptoms and the Quality of Life in Irritable Bowel Syndrome Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2022, 14, 2618.	4.1	11
78	An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. European Journal of Clinical Pharmacology, 2021, 77, 717-725.	1.9	10
79	Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression. Neuropharmacology, 2021, 194, 108447.	4.1	10
80	Differentiating Myoclonus from Tics. Psychological Reports, 2000, 86, 155-156.	1.7	9
81	A Qualitative and Quantitative Review of Obstetric Complications and Autistic Disorder. Journal of Developmental and Physical Disabilities, 2007, 19, 337-364.	1.6	9
82	The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina (Lithuania), 2022, 58, 213.	2.0	9
83	Unilateral auditory hallucinations in a boy with ipsilateral conductive hearing loss Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 302-302.	1.9	8
84	Clinical Assessment of TICS. Psychological Reports, 2001, 89, 48-50.	1.7	8
85	Documentation of Demographic Data. Psychological Reports, 2003, 93, 151-152.	1.7	8
86	Monitoring People Treated with Isotretinoin for Depression. Psychological Reports, 2007, 100, 1312-1314.	1.7	8
87	A Review of the Literature and a Preliminary Study of Family Compliance in a Developmental Disabilities Clinic. Psychological Reports, 1998, 82, 275-286.	1.7	7
88	Clinical Assessment of Adventitious Movements. Psychological Reports, 1998, 83, 739-750.	1.7	7
89	Risks of the Consumption of Beverages Containing Quinine. Psychological Reports, 2003, 93, 1022-1024.	1.7	7
90	Reliable Classification of Case-Control Studies of Autistic Disorder and Obstetric Complications. Journal of Developmental and Physical Disabilities, 2006, 18, 355-381.	1.6	7

#	Article	IF	CITATIONS
91	Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study. Brain Sciences, 2022, 12, 314.	2.3	7
92	Neurobehavioral Assessment of Children and Adolescents Attending a Developmental Disabilities Clinic. Psychological Reports, 2004, 95, 1079-1086.	1.7	6
93	Documentation of Ethnicity. Psychological Reports, 2004, 95, 859-861.	1.7	5
94	Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease. , 2014, , 407-416.		5
95	Human Brain Imaging of Autism Spectrum Disorders. , 2014, , 373-406.		5
96	A cholecystokinin B receptor antagonist and cocaine interaction, phase I study. CNS Neuroscience and Therapeutics, 2019, 25, 136-146.	3.9	5
97	Dataset of quantitative structured office measurements of movements in the extremities. Data in Brief, 2020, 31, 105876.	1.0	5
98	DOCUMENTATION OF DEMOGRAPHIC DATA. Psychological Reports, 2003, 93, 151.	1.7	5
99	Assessing the Quality of the Administration of Psychoactive Medication. Journal of Developmental and Physical Disabilities, 2003, 15, 185-205.	1.6	4
100	Psychoactive Medication Quality Assurance Rating Survey (PQRS) Screening Criteria. Journal of Developmental and Physical Disabilities, 2003, 15, 231-254.	1.6	4
101	Genetic Causes of Autism and the Pervasive Developmental Disorders. , 1990, , 183-216.		4
102	DOCUMENTATION OF ETHNICITY. Psychological Reports, 2004, 95, 859.	1.7	4
103	The Nicotine Hypothesis. , 2014, , 313-332.		3
104	Precision medicine to identify optimal diagnostic and therapeutic interventions for Parkinson's Disease. Medical Science and Discovery, 2021, 8, 514-519.	0.1	3
105	The Increased Likelihood of Obstetric Complications in Autistic Disorder. Southern Medical Journal, 2003, 96, S34.	0.7	3
106	CLINICAL ASSESSMENT OF TICS. Psychological Reports, 2001, 89, 48.	1.7	3
107	NEUROBEHAVIORAL ASSESSMENT OF CHILDREN AND ADOLESCENTS ATTENDING A DEVELOPMENTAL DISABILITIES CLINIC. Psychological Reports, 2004, 95, 1079.	1.7	3
108	Nuclear neurotransmitter molecular imaging of autism spectrum disorder. AIMS Molecular Science, 2019, 6, 87-106.	0.5	3

JAMES ROBERT BRASIC

#	Article	IF	CITATIONS
109	The Urgent Need for Molecular Imaging to Confirm Target Engagement for Clinical Trials of Fragile X Syndrome and Other Subtypes of Autism Spectrum Disorder. Archives of Neuroscience, 2019, 6, .	0.3	3
110	Classification of extremity movements by visual observation of signals and their transforms. MethodsX, 2022, 9, 101739.	1.6	3
111	Suicide is probably more common in untreated youths than in those receiving treatment: The need for a retrospective epidemiological study. Medical Hypotheses, 2005, 65, 1204-1205.	1.5	2
112	The Diagnosis of Esophageal Cancer by 2-deoxy-2-F-18 Fluoro-D-glucose Positron Emission Tomography (F-18 FDG PET). Clinical Nuclear Medicine, 2006, 31, 566-567.	1.3	2
113	Screening People with Disturbed Sleep for Depression. Perceptual and Motor Skills, 2006, 103, 765-766.	1.3	2
114	Differentiation of Non-Pharmacological from Pharmacological Dopamine Release in the Living Human Brain. Current Medical Imaging, 2011, 7, 104-106.	0.8	2
115	Neurotransmitter visualization in schizophrenia. Journal of Biomedical Graphics and Computing, 2013, 3, .	0.2	2
116	Brain PET Imaging in the Cannabinoid System. , 2014, , 27-36.		2
117	Characterization of dose dependent norepinephrine transporter blockade by atomoxetine in human brain using 11C MeNER PET. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S599-S599.	4.3	2
118	Spectral analysis with a minimal basis functions approach for quantification of ligand-receptor dynamic PET study. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S634-S634.	4.3	2
119	Differentiation of Zaghrouta, Ululation to Express Joy in the Middle East, from Movement Disorders and Other Conditions. International Journal of Health and Life Sciences, 2020, 7, .	0.5	2
120	CLINICAL ASSESSMENT OF ADVENTITIOUS MOVEMENTS. Psychological Reports, 1998, 83, 739.	1.7	2
121	Do Families Comply with Child and Adolescent Psychopharmacology?. Child and Adolescent Psychopharmacology News, 2001, 6, 6-10.	0.1	1
122	Differentiation of Zaghrouta, an Expression of Happiness by Women in the Middle East, from Medical Disease. Southern Medical Journal, 2003, 96, S35.	0.7	1
123	Is stalking preventable?. Medical Hypotheses, 2005, 64, 878-879.	1.5	1
124	Does Stimulant Medication Decrease the Lower Extremity Response Times of Children with and without Attention-Deficit/Hyperactivity Disorder?. Perceptual and Motor Skills, 2007, 104, 67-68.	1.3	1
125	Neuroreceptor imaging of schizophrenia. , 0, , 78-87.		1
126	MEASUREMENT OF CEREBRAL EXPRESSION OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 5 IN AUTISM SPECTRUM DISORDER AND FRAGILE X SYNDROME. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, S257.	0.5	1

#	Article	IF	CITATIONS
127	Guidelines for the Diagnosis and Treatment of Parkinson's Disease. , 2021, 9, .		1
128	Beneficial and Adverse Effects of Pets. Psychological Reports, 2002, 91, 444-444.	1.7	0
129	Obtaining Funding for New Researchers in Psychology. Psychological Reports, 2003, 93, 276-278.	1.7	0
130	Inverted-U shape relation links impulsivity and dopamine receptor availability in ventral striatum. NeuroImage, 2010, 52, S109.	4.2	0
131	Parcellation of functional subdivisions of cingulate cortex and their agreements with distributions of multiple receptor systems. NeuroImage, 2010, 52, S194.	4.2	0
132	Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. International Journal of Physical Medicine & Rehabilitation, 2018, 06, .	0.5	0
133	The Courage to Prevail. Oncologist, 2021, 26, 988-989.	3.7	0
134	BENEFICIAL AND ADVERSE EFFECTS OF PETS. Psychological Reports, 2002, 91, 444.	1.7	0
135	OBTAINING FUNDING FOR NEW RESEARCHERS IN PSYCHOLOGY Division of Nuclear Medicine Russell H. Morgan Department of Radiology and Radiological Science Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Psychiatry Bellevue Hospital Center and the New York University School of Medicine. Psychological Reports. 2003. 93. 276.	1.7	0
136	Learning Mechanisms Underlying Value-Driven Attention. Journal of Vision, 2017, 17, 1101.	0.3	0
137	Reply to Aljabali et al. Comment on "Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina 2022, 58, 213― Medicina (Lithuania), 2022, 58, 793.	2.0	0